BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruan Y, Kim HN, Ogana H, Kim YM. Wnt Signaling in Leukemia and Its Bone Marrow Microenvironment. Int J Mol Sci 2020;21:E6247. [PMID: 32872365 DOI: 10.3390/ijms21176247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Skelding KA, Barry DL, Theron DZ, Lincz LF. Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia. Int J Mol Sci 2022;24. [PMID: 36614005 DOI: 10.3390/ijms24010563] [Reference Citation Analysis]
2 Shahid AM, Um IH, Elshani M, Zhang Y, Harrison DJ. NUC-7738 regulates β-catenin signalling resulting in reduced proliferation and self-renewal of AML cells. PLoS One 2022;17:e0278209. [PMID: 36520954 DOI: 10.1371/journal.pone.0278209] [Reference Citation Analysis]
3 Mengxuan S, Fen Z, Runming J. Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era. Front Pediatr 2022;10:923419. [DOI: 10.3389/fped.2022.923419] [Reference Citation Analysis]
4 Li C, Wang M, Shi Y, Xin H. SOSTDC1 acts as a tumor inhibitor in acute myeloid leukemia by downregulating the Wnt/β-catenin pathway. Environ Toxicol 2022. [PMID: 35442555 DOI: 10.1002/tox.23540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ruan Y, Chen L, Xie D, Luo T, Xu Y, Ye T, Chen X, Feng X, Wu X. Mechanisms of Cell Adhesion Molecules in Endocrine-Related Cancers: A Concise Outlook. Front Endocrinol 2022;13:865436. [DOI: 10.3389/fendo.2022.865436] [Reference Citation Analysis]
6 Yao Y, Huang T, Wang Y, Wang L, Feng S, Cheng W, Yang L, Duan Y. Angiogenesis and anti-leukaemia activity of novel indole derivatives as potent colchicine binding site inhibitors. J Enzyme Inhib Med Chem 2022;37:652-65. [PMID: 35109719 DOI: 10.1080/14756366.2022.2032688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mojtahedi H, Yazdanpanah N, Rezaei N. Chronic myeloid leukemia stem cells: targeting therapeutic implications. Stem Cell Res Ther 2021;12. [DOI: 10.1186/s13287-021-02659-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Huang Y, Wang Y, Tang J, Qin S, Shen X, He S, Ju S. CAM-DR: Mechanisms, Roles and Clinical Application in Tumors. Front Cell Dev Biol 2021;9:698047. [PMID: 34295898 DOI: 10.3389/fcell.2021.698047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mohamad SFS, Elias MH. Potential treatment for chronic myeloid leukemia using microRNA: in silico comparison between plants and human microRNAs in targeting BCR-ABL1 gene. Egypt J Med Hum Genet 2021;22. [DOI: 10.1186/s43042-021-00156-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Kim HN, Ruan Y, Ogana H, Kim YM. Cadherins, Selectins, and Integrins in CAM-DR in Leukemia. Front Oncol 2020;10:592733. [PMID: 33425742 DOI: 10.3389/fonc.2020.592733] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]